ClinicalTrials.gg
RecruitingNCT05209243START-METUpdated May 19, 2023

START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC

An interventional study of SBRT and STANDARD OF CARE in Prostate Cancer and Stereotactic Body Radiation Therapy, sponsored by Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic. Recruiting at 2 sites in Spain. Open to male participants. Per ClinicalTrials.gov, last updated 2023-05-19.

Sponsored by Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
266
Allocation
Randomized
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 312 studies in Prostatic Neoplasms with a site in Spain — 72 open to participants now, 126 under way, 45 of them phase 3. Prostatic Neoplasms · Spain.

Planned enrollment
130th of 257
266 · median 268
Started
2023
with 20 others
No phase
25 of 312
8 open now
Primary completion
2025-01
later than 26 of 125 live
Registered
217th of 312
by date

Among the 312 studies in Prostatic Neoplasms with a site in Spain, this one is the 130th largest by planned enrollment of the 257 interventional ones that give a count, is one of 21 that started in 2023, is one of 25 with no phase, reaches primary completion later than 26 of the 125 other live ones, and was the 217th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

72 of the 312 studies in Prostatic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Prostatic Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients and second generation hormonal treatments (Apalutamide/Abiraterone+Prednisone/Enzalutamide) vs androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients plus second generation hormonal treatments, for the treatment of oligometastatic prostate cancer.

Read the detailed description

A total of 266 patients with a histological diagnosis of metastatic hormone sensitive prostate cancer, with limited disease (≤ 3 lesions based on CT and Bone Scan and ≤ 5 lesions based on Choline or PSMA PET/TC) at the diagnosis or in an oligorrecurrent stage will be included in the study. Candidates will be first screened for metastatic sites through bone scintigraphy and computerised tomography (CT) scans. Those who meet the ≤3 metastatic sites criteria will be second screened for metastatic sites based on Choline or PSMA PET/TC, which will be used to define the treatment volume of metastatic disease with SBRT/HIGRT and to confirm the oligometastatic status before the inclusion in the study.

Once included in the study, patients will be randomize (1:1) to standard of care + SBRT vs standard of care.

  • Interventional arm: STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment
  • Control arm: STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

Patients will be stratified according to prior local treatment (yes/no) or the new imaging technique used (Choline vs PSMA PET/TC).

03

Conditions studied

  • Prostate Cancer
  • Stereotactic Body Radiation Therapy

Browse trials for

Keywords

  • SBRT
  • Prostate cancer
  • Metastatic hormonosensitive prostate cancer
  • Second generation hormonal treatments
  • Oligometastatic prostate cancer
  • Apalutamide
  • Enzalutamide
  • Darolutamide
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a histological diagnosis of prostate cancer.
  2. Castration sensitive prostate cancer patients.
  3. Oligometastatic disease defined as less than or equal 3 lesions based on CT and Bone Scan and less than or equal 5 lesions based on Choline or PSMA PET/TC. Bone (including the spine) or/and lymph nodes metastases.
  4. is obtained from the patient.
  5. Adequate bone-marrow, liver and renal function:

    • ≥10 g/dL, Leucocytes ≥ 2000/mm\^3, Neutrophils ≥1500/mm\^3, ≥1000007mm\^3
    • GOT, GPT and Total Bilirrubin ≤1.5* (Upper limit of normality)
    • Creatinine ≤1.5*ULN or ≥50 ml/min\^-1

Exclusion criteria

Exclusion Criteria:

  1. Lack of a histological diagnosis of prostate cancer.
  2. Castration resistant prostate cancer patients according to PCWG3[30].
  3. disease defined as greater than or equal 3 lesions based on CT and Bone Scan and greater than or equal 5 lesions based on Choline or PSMA PET/TC.
  4. Visceral metastases.
  5. Tumor stage T4 according to AJCC 8th Edition Cancer staging form.
  6. Prior treatment with docetaxel, second generation hormonal treatments (Apalutamide/Abiraterone+Prednisone/Enzalutamide) or bone antiresorptive therapy.
  7. Presence of symptoms or signs that are indicative of urgent surgery/radiotherapy as the first treatment for the metastases disease.
  8. Lesions that require SBRT treatment that exceed critical organ tolerance limits, or do not meet the criteria for the prescription of SBRT techniques used.
  9. History of another neoplastic pathology which is not a currently controlled with the exception basal cell carcinomas.
  10. Presence of a cardiopathy or metabolic disorder that does not recommend the treatment with second generation hormonal treatments, or the presence of inflammatory bowel disease or other pathology that does not recommend the treatment with radiotherapy.
  11. Lack of or the patient's ability to give consent.
  12. Participation in other clinical trials at the time of inclusion or in the 3 previous months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
266 participants (estimated)

Study arms

  • Experimental
    Interventional arm

    STANDARD OF CARE + SBRT (all metastatic lesions). ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

    Radiation: SBRT · Radiation: STANDARD OF CARE

  • Active comparator
    Control arm

    STANDARD OF CARE. ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

    Radiation: STANDARD OF CARE

Interventions

  • RadiationSBRT

    SBRT (all metastatic lesions)

  • RadiationSTANDARD OF CARE

    ADT+ RT to the primary tumor (previously not treated) + Second generation hormonal treatment

06

What researchers measure

Primary outcomes

  1. Radiological progression-free survival (rPFS)

    based on RECIST 1.1 criteria

    Time frame: An average of two years

Secondary outcomes

  1. Overall survival

    Defined as the time from trial randomization to the date of death from any cause. Patients not experiencing an event will be censored at the last known time they were alive.

    Time frame: 3 years

  2. Time to cytotoxic chemotherapy

    Time from trial randomization to start of first cytotoxic chemotherapy

    Time frame: An average of two years

  3. Time to PSA progression

    Counted from the day of randomization to the day of either first recorded biochemical progression\[30\]. Patients not experiencing a biochemical failure are censored at time of last assessment

    Time frame: An average of two years

  4. Local control

    based on RECIST 1.1 criteria

    Time frame: 3 years

  5. Time to castration resistance

    Defined as the time from trial randomization until castration resistant status

    Time frame: 3 years

  6. Time to skeletal-related event

    Time from randomization until the occurrence of a skeletal related event (SRE)

    Time frame: An average of two years

  7. Quality of life. FACT-P

    FACT-P

    Time frame: Three years after the study completion

  8. Safety profile

    To determine acute and late toxicity due to radiotherapy, scored using the Common Terminology Criteria for Adverse Events (CTCAE) versión 4.3.

    Time frame: Three years after the study completion

  9. Pain. BPI

    Evaluate the impact of the treatment on the patient's quality of life using the Brief Pain Inventory (BPI) questionnaire

    Time frame: Three years after the study completion

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2025, 24 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 24 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2022
First posted
Jan 26, 2022
StartActual
Jan 26, 2023
Primary completionEst.
Jan 2025
CompletionEst.
Jan 2027
Last update
May 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05209243
Lead sponsor
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Responsible party
Sponsor
First posted
Jan 26, 2022
Start date
Jan 26, 2023
Primary completion
Jan 2025 (estimated)
Completion
Jan 2027 (estimated)
Last update
May 19, 2023

Study contacts

Antonio J Conde Moreno, MD PhD
Contact
antoniojconde@gmail.com
+34 649039866
Fernando López Campos, MD PhD
Contact
fernando_lopez_campos@hotmail.com
+34 663158959
Antonio J Conde Moreno, MD PhD
principal investigator · Grupo de Investigación Clínica en Oncología Radioterápica
Fernando López Campos, MD PhD
principal investigator · Grupo de Investigación Clínica en Oncología Radioterápica
Alfonso Gómez-Iturriaga, MD PhD
principal investigator · Grupo de Investigación Clínica en Oncología Radioterápica

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion